Sat.May 16, 2020 - Fri.May 22, 2020

article thumbnail

Episode 9 – Part Two – Telemedicine, Covid-19 and the Future of Medical Devices

Medical Device Success

Reading time: 2 – 2 minutes Telemedicine installations in 30 countries in less that two months because of Covid-19!! That doesn’t include sales in the US. In episode 9, Eric Bacon, President of AMD Global Telemedicine takes us further into this rapidly changing and growing market. Comments and questions are welcome! Now Go Win Your Week! If you have a need for biotech, pharma, device or any life science company data, check out BioPharmGuy.

Medical 100
article thumbnail

Sales for the Non-Sales-Oriented: Preparing Our Service Team for Client Satisfaction

The Brooks Group

As you read this, businesses across the country are taking the first tentative steps toward “reopening” – though the definition of what constitutes this varies from company to company. In most cases, “reopening” refers to the restoration of operations that involves some level of human-to-human contact – a dicey proposition given the ongoing desire by most to social distance.

Sales 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharma Now: How the Industry Will Recover and Adapt

Salesforce

In late January, I wrote a blog titled Trends Impacting Pharma in 2020. Now, in May, we see how quickly things can change. In response to COVID-19, the pharmaceutical industry has accelerated its digital transformation to address what are now not just trends, but imperatives — like patient-centricity and virtual engagement. Last month, at EyeforPharma, North America’s largest commercial pharma event (which became a virtual event due to the coronavirus), I listened to industry leaders

Pharma 52
article thumbnail

Bringing Therapies from Bench to Bedside: Navigating Challenges in the Last Mile

Clarify Health

Imagine your company was presented with an investment opportunity. The proposition: commit several hundred million dollars over 10-12 years for the potential to make billions of dollars annually for the following decade. The catch: there is a ~95% chance that you could lose everything. What would you do? Most companies would run in the [.].

Pharma 52
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Factors Affecting Sales Compensation Planning for the COVID-19 Road to Recovery

The Marketing Advantage

May 21, 2020 As the country looks ahead to life after the COVID-19 pandemic, the sales incentive compensation plans that carried pharma, biotech and medical device companies through the pandemic will need to be adjusted as sales representatives begin returning to the field. However, there are a number of factors affecting the road to recovery that extend to the sales compensation planning process.

Sales 52
article thumbnail

Bringing Therapies from Bench to Bedside: Navigating Challenges in the Last Mile

Clarify Health

Imagine your company was presented with an investment opportunity. The proposition: commit several hundred million dollars over 10-12 years for the potential to make billions of dollars annually for the following decade. The catch: there is a ~95% chance that you could lose everything. What would you do? Most companies would run in the other direction, let alone create an entire business around this investment model.